The role of MT1-MMP in the progression and metastasis of osteosarcoma

Abstract

The dysregulation of Membrane - type 1 matrix metalloproteinase (MT1-MMP) has been extensively studied in numerous cancer types, and plays key roles in angiogenesis, cancer progression, and metastasis. MT1-MMP is a predictor of poor prognosis in osteosarcoma (OS), yet the molecular mechanisms of disease progression are unclear. This review provides a summary of the literature relating to the gene and protein expression of MT1-MMP (MMP-14) in OS clinical samples, evaluates the expression in cell lines and experimental models, and analyses its potential role in the progression and metastasis of OS. In addition, the therapeutic potential of MT1-MMP as a drug target has been assessed. Due to the biological complexity of MMPs, inhibition has proven to be challenging. However, exploiting the expression and proteolytic capacity of MT1-MMP could open new avenues in the search for novel, safer and selective drugs for use in OS.

Keywords

Matrix metalloproteinase / membrane-type / osteosarcoma / MT1-MMP

References

[1] Misaghi A,Awad M.Osteosarcoma: a comprehensive review.SICOT J2018;4:12 PMCID:PMC5890448

[2] UK CR. Bone sarcoma statistics. Available from: https://www.cancerresearchuk.org/ [Last accessed on 6 Dec 2021]

[3] Visse R,Murphy G.Structure and function of matrix metalloproteinases and TIMPs.Cardiovasc Res2006;69:562-73

[4] Cerami E,Dogrusoz U.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.Cancer Discov2012;2:401-4 PMCID:PMC3956037

[5] Gao J,Dogrusoz U.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.Sci Signal2013;6:pl1 PMCID:PMC4160307

[6] Kilpinen S,Ojala K.Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues.Genome Biol2008;9:R139 PMCID:PMC2592717

[7] Gonzalez-Molina J,Liao Z,Ojala PM.MMP14 in sarcoma: a regulator of tumor microenvironment communication in connective tissues.Cells2019;8:991 PMCID:PMC6770050

[8] Alaseem A,Dondapati P,Bishayee A.Matrix metalloproteinases: a challenging paradigm of cancer management.Semin Cancer Biol2019;56:100-15

[9] Gong Y,Oh WK.Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.Cancers (Basel)2014;6:1298-327 PMCID:PMC4190542

[10] Wang J,Yuan TX.Matrix metalloproteinase 9 (MMP-9) in osteosarcoma: review and meta-analysis.Clin Chim Acta2014;433:225-31

[11] Zhang M.Association of MMP-2 expression and prognosis in osteosarcoma patients.Int J Clin Exp Pathol2015;8:14965-70 PMCID:PMC4713615

[12] Uchibori M,Nagasaka T,Nakanishi K.Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.Int J Oncol2006;

[13] Futamura N,Urakawa H.EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma.Tumour Biol2014;35:5159-65

[14] Bjørnland K,Pettersen S,Fodstad O.Matrix metalloproteinases participate in osteosarcoma invasion.J Surg Res2005;127:151-6

[15] Xiao X,Zhang H.Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.Tumour Biol2015;36:2427-35

[16] Choy E,MacConaill L.High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.Cancer2012;118:2905-14 PMCID:PMC3272156

[17] Ho XD,Q Le V.Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and normal bone samples.Exp Biol Med (Maywood)2017;242:1802-11 PMCID:PMC5714151

[18] Engelholm LH,Hald A.Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180.J Pathol2016;238:120-33

[19] Biswas S,Long A.Abstract 5580: Membrane-Type 1 Matrix Metalloproteinase (MT1-MMP): a predictive biomarker of chemotherapy response in osteosarcoma.Cancer Res2012;72:5580

[20] Wen X,Yu K.Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis.Tumour Biol2014;35:845-8

[21] Li H,Liu LH.A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma.Tumour Biol2014;35:5487-91

[22] Liu Y,Teng Z.Matrix metalloproteinase 9 expression and survival of patients with osteosarcoma: a meta-analysis.Eur J Cancer Care (Engl)2017;26:e12364

[23] Yamamoto Y,Tajima K.Characterization of human multicentric osteosarcoma using newly established cells derived from multicentric osteosarcoma.J Cancer Res Clin Oncol2011;137:423-33

[24] Mohseny AB,Cai Y.Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.Lab Invest2011;91:1195-205

[25] Lauvrak SU,Kresse SH.Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes.Br J Cancer2013;109:2228-36 PMCID:PMC3798956

[26] Giambernardi TA,Taylor GP.Overview of matrix metalloproteinase expression in cultured human cells.Matrix Biol1998;16:483-96

[27] Matsumoto Y,Harimaya K,Matsuda S.Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells.Jpn J Cancer Res2001;92:429-38 PMCID:PMC5926729

[28] Petrova V,Melino G.The hypoxic tumour microenvironment.Oncogenesis2018;7:10 PMCID:PMC5833859

[29] Chan CD,Tensaout HA.Co-localisation of intra-nuclear membrane type-1 matrix metalloproteinase and hypoxia inducible factor-2α in osteosarcoma and prostate carcinoma cells.Oncol Lett2021;21:158 PMCID:PMC7798041

[30] Ingvarsen SZ,van Putten S.Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis.Sci Rep2020;10:19138 PMCID:PMC7645741

[31] Wang X,Yi Z.WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway.Cell Biol Int2018;42:598-607

[32] Enomoto M,Itsukushima S.Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.Oncogene2009;28:3197-208

[33] Ren D,Nishita M.Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition.Genes Cells2011;16:304-15

[34] Liu P,Pei J,Wilson MJ.Regulation of MT1-MMP activity by β-catenin in MDCK non-cancer and HT1080 cancer cells.J Cell Physiol2010;225:810-21 PMCID:PMC2939945

[35] Guo Y,Koontz Z.Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells.J Orthop Res2007;25:964-71

[36] Liu B,Wang X.A furin inhibitor downregulates osteosarcoma cell migration by downregulating the expression levels of MT1-MMP via the Wnt signaling pathway.Oncol Lett2014;7:1033-8 PMCID:PMC3961323

[37] Lin CH,Chen C.Wnt signaling in osteosarcoma. In: Kleinerman MDE, editor. Current advances in osteosarcoma. Cham: Springer International Publishing; 2014. p. 33-45.

[38] Rubin EM,Tu K,Zi X.Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma.Mol Cancer Ther2010;9:731-41 PMCID:PMC2837364

[39] Tsuge M,Sasaki R,Okada F.SK-216, a novel inhibitor of plasminogen activator inhibitor-1, suppresses lung metastasis of human osteosarcoma.Int J Mol Sci2018;19:736 PMCID:PMC5877597

[40] Brennecke P,Campanile C.CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice.Clin Exp Metastasis2014;31:339-49 PMCID:PMC3915086

[41] Zhang F,Chen J,Guo F.SiRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells.Asian Pac J Cancer Prev2011;12:239-45

[42] Zhang F,Chen J,Guo F.Influence of β-catenin small interfering RNA on human osteosarcoma cells.J Huazhong Univ Sci Technolog Med Sci2011;31:353-8

[43] Ladhani O,Orgaz JL,Volpert OV.Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis.Neoplasia2011;13:633-42 PMCID:PMC3132849

[44] Tan ML,Dass CR.Anti-chondrosarcoma effects of PEDF mediated via molecules important to apoptosis, cell cycling, adhesion and invasion.Biochem Biophys Res Commun2010;398:613-8

[45] Alcantara MB,Elahy M.Pigment epithelium-derived factor upregulates collagen I and downregulates matrix metalloproteinase 2 in osteosarcoma cells, and colocalises to collagen I and heat shock protein 47 in fetal and adult bone.J Pharm Pharmacol2014;66:1586-92

[46] Xie Y,Deng Z,Hu C.MiR-302b suppresses osteosarcoma cell migration and invasion by targeting Runx2.Sci Rep2017;7:13388 PMCID:PMC5645461

[47] Xu E,Ma J.miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3.Oncol Rep2016;35:275-83

[48] Elenjord R,Johansen HT.Collagen I regulates matrix metalloproteinase-2 activation in osteosarcoma cells independent of S100A4.FEBS J2009;276:5275-86

[49] Bjørnland K,Odegaard OT.S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme.Cancer Res1999;59:4702

[50] Mathisen B,Hansen J.S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells.Clin Exp Metastasis2003;20:701-11

[51] Loennechen T,Hansen J.Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in osteosarcoma cells in an S100A4-independent manner.Biochem Pharmacol2003;66:2341-53

[52] Bratland Å,Bjørnland K.The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells.Clin Exp Metastasis2003;20:541-7

[53] Parks WC,López-Boado YS.Matrix metalloproteinases as modulators of inflammation and innate immunity.Nat Rev Immunol2004;4:617-29

[54] Dass CR,Choong PF.c-Jun knockdown sensitizes osteosarcoma to doxorubicin.Mol Cancer Ther2008;7:1909-12

[55] Dass CR,Khachigian LM,Choong PF.Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model.Cancer Biol Ther2008;7:1033-6

[56] Dass CR,Galloway SJ.Dz13 induces a cytotoxic stress response with upregulation of E2F1 in tumor cells metastasizing to or from bone.Oligonucleotides2010;20:79-91

[57] Tan ML,Dass CR.Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours.Cancer Cell Int2010;10:9 PMCID:PMC2861053

[58] Zhang G,Sumithran E.Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression.Oncogene2006;25:7260-6

[59] Fromigué O,Marie PJ.Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion.J Biol Chem2008;283:30549-56 PMCID:PMC2662148

[60] Tsubaki M,Itoh T.Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.Toxicol Appl Pharmacol2012;259:402-10

[61] Meyers PA,Chou AJ.Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.Cancer2011;117:1736-44 PMCID:PMC3059356

[62] Heikkilä P,Hirn MY.Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate.J Surg Res2003;111:45-52

[63] Cheng YY,Lee KM,Kumta SM.Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines.Pediatr Blood Cancer2004;42:410-5

[64] Xin ZF,Jung ST.Risedronate inhibits human osteosarcoma cell invasion.J Exp Clin Cancer Res2009;28:105 PMCID:PMC2729740

[65] Linder S.MT1-MMP: Endosomal delivery drives breast cancer metastasis.J Cell Biol2015;211:215-7 PMCID:PMC4621844

[66] Sheehy S.A transcriptional regulatory role for the membrane type-1 matrix metalloproteinase in carcinogen-induced inflammasome gene expression.Gene Regul Syst Bio2017;11:1177625017713996 PMCID:PMC5467917

[67] ICONIC: Improving outcomes through collaboration in osteosarcoma. Available from: https://ClinicalTrials.gov/show/NCT04132895 [Last accessed on 6 Dec 2021]

[68] Biology of osteosarcoma (BOOST) registry and biobank. Available from: https://clinicaltrials.gov/ct2/show/NCT03225872 [Last accessed on 6 Dec 2021]

[69] Beech T. Patient/parent osteosarcoma genome-wide registry (POWR) provides the sarcoma community with an underutilized resource for genomic and medical history data. Available from: https://becauseofdaniel.org/the-science-of-powr/ [Last accessed on 6 Dec 2021]

[70] Gill J,Geller D.New targets and approaches in osteosarcoma.Pharmacol Ther2013;137:89-99

[71] Howard SC,Pui CH,Harvey RD.Preventing and managing toxicities of high-dose methotrexate.Oncologist2016;21:1471-82 PMCID:PMC5153332

[72] Sowers R,Richardson C.Impairment of methotrexate transport is common in osteosarcoma tumor samples.Sarcoma2011;2011:834170 PMCID:PMC3017953

[73] Winer A,Mignatti P.Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes.Mol Cancer Ther2018;17:1147-55 PMCID:PMC5984693

[74] Fields GB.The Rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma.Cells2019;8:984 PMCID:PMC6769477

[75] BT1718 in patients with advanced solid tumours. Available from: https://ClinicalTrials.gov/show/NCT03486730 [Last accessed on 6 Dec 2021]

[76] Bennett G,Lutz B,Keen N.Abstract B135: The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumors expressing MT1-MMP.Mol Cancer Ther2018;17:B135

[77] Atkinson JM,Edwards DR.Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.Cancer Res2010;70:6902-12 PMCID:PMC2933508

[78] Gill JH,Shnyder SD.Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity.Mol Pharm2014;11:1294-300

[79] Li S,Meng X.Targeted methotrexate prodrug conjugated with heptamethine cyanine dye improving chemotherapy and monitoring itself activating by dual-modal imaging.Front Mater2018;5:35